CRIS Current Research Information System

MUSOLINO, ANTONINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.358
NA - Nord America 3.742
EU - Europa 1.811
SA - Sud America 577
Continente sconosciuto - Info sul continente non disponibili 321
AF - Africa 94
OC - Oceania 9
Totale 12.912
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.571
VN - Vietnam 2.085
SG - Singapore 1.355
CN - Cina 1.298
IT - Italia 758
HK - Hong Kong 458
BR - Brasile 451
BD - Bangladesh 415
KR - Corea 272
GB - Regno Unito 258
FR - Francia 159
IN - India 159
DE - Germania 139
JP - Giappone 115
FI - Finlandia 99
RU - Federazione Russa 74
CA - Canada 68
SE - Svezia 65
NL - Olanda 61
MX - Messico 52
AR - Argentina 43
ZA - Sudafrica 32
IE - Irlanda 31
PH - Filippine 29
AT - Austria 28
ES - Italia 25
TH - Thailandia 24
UA - Ucraina 23
EE - Estonia 22
EC - Ecuador 20
TR - Turchia 20
IQ - Iraq 18
ID - Indonesia 17
CO - Colombia 16
JM - Giamaica 16
PK - Pakistan 15
CH - Svizzera 14
PY - Paraguay 13
TW - Taiwan 13
SA - Arabia Saudita 12
VE - Venezuela 12
SC - Seychelles 11
CI - Costa d'Avorio 10
AU - Australia 9
CL - Cile 9
PL - Polonia 9
TG - Togo 9
UZ - Uzbekistan 9
JO - Giordania 7
BO - Bolivia 6
CR - Costa Rica 6
LT - Lituania 6
PT - Portogallo 6
TN - Tunisia 6
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
BE - Belgio 5
GT - Guatemala 5
NP - Nepal 5
BG - Bulgaria 4
CZ - Repubblica Ceca 4
EG - Egitto 4
ET - Etiopia 4
HN - Honduras 4
KZ - Kazakistan 4
MA - Marocco 4
MY - Malesia 4
RO - Romania 4
DZ - Algeria 3
GR - Grecia 3
KE - Kenya 3
LB - Libano 3
NI - Nicaragua 3
OM - Oman 3
AG - Antigua e Barbuda 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
IR - Iran 2
MN - Mongolia 2
MW - Malawi 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BW - Botswana 1
BZ - Belize 1
CU - Cuba 1
CY - Cipro 1
DM - Dominica 1
GE - Georgia 1
GH - Ghana 1
HR - Croazia 1
HT - Haiti 1
HU - Ungheria 1
Totale 12.576
Salva come PNG Salva come JPEG
Città #
Singapore 846
Hefei 633
Ho Chi Minh City 585
Hanoi 484
Hong Kong 433
San Jose 385
Ashburn 351
Seoul 262
Southend 211
Santa Clara 206
Council Bluffs 164
Fairfield 143
Los Angeles 102
Tokyo 100
New York 98
Bologna 97
Beijing 94
Milan 92
Lauterbourg 90
Houston 87
Boardman 81
Dallas 74
Helsinki 73
Seattle 73
Wilmington 69
Woodbridge 68
Da Nang 64
Chandler 61
Bengaluru 60
Haiphong 58
Cambridge 57
Buffalo 56
Dong Ket 54
Rome 49
Princeton 47
Ha Long 45
São Paulo 44
Chicago 37
Mexico City 34
Biên Hòa 33
Can Tho 32
Dublin 31
Ninh Bình 29
Ann Arbor 28
Atlanta 27
Hải Dương 27
Quận Bình Thạnh 26
Vũng Tàu 25
Redondo Beach 24
Thái Nguyên 24
Westminster 23
Lappeenranta 22
Nuremberg 22
Frankfurt am Main 21
Padova 20
San Francisco 20
The Dalles 20
Nanjing 19
Quận Phú Nhuận 19
Amsterdam 18
Tongling 18
Vienna 18
Medford 17
Turin 17
Điện Bàn 17
Miano 16
San Diego 16
Shanghai 16
Changsha 15
Toronto 15
Vinh 15
Bắc Ninh 14
Phoenix 14
Shenyang 14
Zhengzhou 14
Bangkok 13
Bắc Giang 13
Guangzhou 13
Orem 13
Quận Bảy 13
Miami 12
Naples 12
Quận Sáu 12
Brooklyn 11
Guayaquil 11
Hyderabad 11
Montreal 11
Phủ Lý 11
Abidjan 10
Falkenstein 10
Nam Định 10
Palermo 10
Thái Bình 10
Baghdad 9
Bern 9
Casalecchio di Reno 9
Florence 9
Huế 9
Kingston 9
Lomé 9
Totale 7.582
Salva come PNG Salva come JPEG
Nome #
A narrative review of the principal glucocorticoids employed in cancer 1.129
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer 383
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 358
Indicators of cure for women living after uterine and ovarian cancers: a population-based study 317
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity 186
Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma 182
The descriptive epidemiology of melanoma in Italy has changed - for the better 174
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 164
Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial 155
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial 155
Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030 155
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 153
ACTIVITY AND SAFETY OF DOSE-ADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DA-POCH-R) IN VERY ELDERLY PATIENTS WITH POOR-PROGNOSTIC UNTREATED DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA 147
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 145
Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study 144
Influence of Sex and Age on Site of Onset, Morphology, and Site of Metastasis in Colorectal Cancer: A Population-Based Study on Data from Four Italian Cancer Registries 141
Lomustine (Chloroethyinitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma 140
Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. 140
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer 132
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 132
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 131
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 129
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? 129
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 129
Salivary microRNA for diagnosis of cancer and systemic diseases: A systematic review 126
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer 125
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 123
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 121
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies 120
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 119
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer - The role of anthrocycline dose intensity 118
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study 118
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study 117
Hypertriglyceridaemia with bexarotene in cutaneos T cell Lymphoma: the role of Omega-3 fatty acids 117
Breast Cancer in Italy: Stage and Region Distribution 116
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer 114
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients 112
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 111
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 108
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 108
Evaluation of an Italian Population-Based Programme for Risk Assessment and Genetic Counselling and Testing for BRCA1/2-Related Hereditary Breast and Ovarian Cancer after 10 Years of Operation: An Observational Study Protocol 107
Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma 106
Role of Fcγ receptors in HER2-targeted breast cancer therapy 106
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer 106
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives 105
Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study 104
PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)] 102
Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population‐based study in Italy 102
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 101
P73 and p53 pathway in human breast cancer 100
The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation 99
The Innate Immune Microenvironment in Metastatic Breast Cancer 99
Trends in Survival and Cure Indicators of Thin and Thick Cutaneous Malignant Melanoma in Italy 98
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 98
HER2 STATUS AS PREDICTOR OF MAMMOGRAPHIC SCREENING DETECTION: COMPARISON OF INTERVAL- AND SCREEN-DETECTED BREAST CANCERS 97
Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations 96
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 96
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer 96
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 95
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 93
Trends in Liver Cancer Incidence and Survival in Italy by Histologic Type, 2003-2017 92
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 90
Immunoglobulin g fragment c receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with Cetuximab-based therapy 89
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 88
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 87
MULTIPLE COLORECTAL-ENDOMETRIAL (CEC) AND YOUNG AGE ONSET ENDOMETRIAL CANCER (EC): ARE THEY A FAMILY MARKER FOR HEREDITARY NON-POLYPOSIS COLORECTAL CARCINOMA SYNDROME (HNPCC)? 87
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study 84
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 83
RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer 80
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 79
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 76
Perspectives, Challenges, and Advances in Therapeutic Strategies for Gynecological Malignant Tumors 74
North-south differences in incidence and surveillance of cutaneous malignant melanoma in Italy 72
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 72
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 71
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 69
Can contralateral prophylactic mastectomy and oophorectomy increase survival in BRCA-related breast cancer? Results from the Italian MUTina study 69
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors 68
Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions 66
NEW PERSPECTIVES OF SELECTION TESTS FOR THE TREATMENT WITH PARP INHIBITORS OF OVARIAN CANCER PATIENTS: A MINI-REVIEW 64
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications 63
Survey on cancer patients’ attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center 62
Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive breast cancers 61
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force 61
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial 58
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 57
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 54
Hormonal Therapy For Endometriosis And The Risk Of Endometriosis-Associated Gynecologic Cancers: A Propensity Score-Adjusted Real-World Data Study 52
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 52
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients 52
Early detection of recurrences in the followup of primary breast cancer in an asymptomatic or symptomatic phase 52
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 52
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 49
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy 49
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype 49
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer 49
Triple negative status and BRCA mutations in contralateral breast cancer: A population-based study 48
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) 48
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 46
Screening children and adolescents for cutaneous malignant melanoma: the impossible trade-off between life-years saved and unnecessary biopsies 44
Totale 11.647
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.432
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.432
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022275 0 0 23 11 50 11 10 39 11 8 45 67
2022/2023273 24 32 15 41 33 26 8 9 53 2 11 19
2023/202468 7 18 3 13 5 4 2 1 4 3 5 3
2024/20251.892 8 79 60 71 203 215 174 104 99 121 221 537
2025/20267.801 1.716 847 709 592 350 228 534 247 933 515 663 467
2026/20271.521 402 938 181 0 0 0 0 0 0 0 0 0
Totale 12.912